| Fortekor Tablets for Dogs & Cats | 
Fortekor is a medication which can be used on cats or dogs but for different ailments. For dogs it is a heart failure medication and in cats is used to treat kidney failure. Dogs that use the medication may have a significantly increased lifespan and cats will find they have an increased appetite and general quality of life. Fortekor works by improving and increasing blood flow throughout the body, essential in both heart and kidney problems.
Fortekor is a small tablet which can be administered on its own or with food for ease and is available in a number of strengths depending on the size of the animal.
There can be some side effects to the medication. Cats may put on weight while using the drug but this is a positive side effect as they may have suffered weight loss with a kidney condition in the first place. Some dogs have suffered fatigue and mild dizziness but no stronger side effects have been noted in animals using the medication. There is a possibility of interaction with other drugs, so animals already on medication should be regularly monitored by a vet.
Fortekor is a prescription-only medication, which means a vet must write a prescription for it. However, it is possible to buy pet drugs online and VioVet supplies discount pet medication. The drug can also be obtained from your veterinary surgeon but this is often the most expensive way of purchasing medication. The prescription must be obtained from the vet and sent to VioVet before you can be supplied with the drug.
| | | | Fortekor Tablets for Dogs & Cats | 2.5mg » Pack of 28
• Usually ships in 24 hours, subject to prescription.
• Veterinary prescription from your vet required. (what's this?) |
£11.22
(inc. VAT) | | 2.5mg » Pack of 56
• Usually ships in 24 hours, subject to prescription.
• Veterinary prescription from your vet required. (what's this?) |
£22.45
(inc. VAT) | | 2.5mg » Priced per Tablet
• Usually ships in 24 hours, subject to prescription.
• Veterinary prescription from your vet required. (what's this?) |
£0.40
(inc. VAT) | | 5mg » Pack of 28
• Usually ships in 24 hours, subject to prescription.
• Veterinary prescription from your vet required. (what's this?) |
£18.31
(inc. VAT) | | 5mg » Pack of 56
• Usually ships in 24 hours, subject to prescription.
• Veterinary prescription from your vet required. (what's this?) |
£36.61
(inc. VAT) | | 5mg » Priced per Tablet
• Usually ships in 24 hours, subject to prescription.
• Veterinary prescription from your vet required. (what's this?) |
£0.65
(inc. VAT) | | 20mg » Pack of 28
• Usually ships in 24 hours, subject to prescription.
• Veterinary prescription from your vet required. (what's this?) |
£39.26
(inc. VAT) | | 20mg » Priced per Tablet
• Usually ships in 24 hours, subject to prescription.
• Veterinary prescription from your vet required. (what's this?) |
£1.56
(inc. VAT) | | |
|  | Customers who purchased these items also purchased |   | | Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction 
Company name: Novartis Animal Health UK Ltd
Address: Frimley Business Park
Frimley
Camberley
Surrey
GU16 7SR
Telephone: 01276 694402
Fax: 01276 694403
Presentation Fortekor 2.5
Palatable beige, ovaloid tablets which are scored on both sides: 2.5 mg benazepril hydrochloride.
Uses
FORTEKOR* is indicated for the treatment of heart failure in dogs and chronic renal insufficiency in cats. The active ingredient is benazepril. After oral administration, benazepril is rapidly absorbed from the gastrointestinal tract and hydrolysed into benazeprilat, a highly specific and potent inhibitor of angiotensin converting enzyme (ACE). FORTEKOR* produces significant inhibition of plasma ACE activity for more than 24 hours after a single dose in cats and dogs. Inhibition of ACE leads to reduced conversion of inactive angiotensin I into angiotensin II and therefore reduction in the effects mediated by angiotensin II, including vasoconstriction of both arteries and veins, retention of sodium and water by the kidney and remodelling effects (including pathological cardiac hypertrophy and degenerative renal changes).
In dogs with heart failure, FORTEKOR* lowers the blood pressure and volume loading on the heart. FORTEKOR* leads to a significant extension of the life span of dogs with heart failure and also improves clinical signs, notably reduction in coughing and improvement of the quality of life.
In contrast with other ACE inhibitors, benazeprilat is excreted equally by both biliary and urinary routes in dogs and primarily via the biliary route in cats and therefore no adjustment of the dose of FORTEKOR* is necessary in the treatment of cats with renal insufficiency.
In cats with chronic renal insufficiency, Fortekor reduces the protein loss in urine and lowers the systemic and intraglomerular blood pressure. Reduction in glomerular hypertension retards the progression of kidney disease by inhibition of further damage to the kidneys. Fortekor increases the appetite, quality of life and the survival time of the cats, particularly in advanced disease.
Dosage and administration
Heart failure in dogs
The recommended dose is 0.25-0.5 mg benazepril hydrochloride/kg bodyweight, to be given orally once daily according to the tabulated heart failure dosage regime:
Heart failure dosage regime
|
| Fortekor 2.5
| Weight of dog (kg)
| Standard dose
| Double dose
| 2.5 - <5
| 0.5 tablet
| 1 tablet
| 5 - 10
| 1 tablet
| 2 tablets
|
FORTEKOR* can be given with or without food. The duration of treatment is unlimited. The dose may be doubled, still administered once daily if judged clinically necessary and advised by the veterinary surgeon. FORTEKOR* may be given in combination with digoxin, diuretics and anti-arrhythmic drugs as necessary.
Chronic renal insufficiency in cats
The recommended dose is 0.5-1.0 mg benazepril hydrochloride/kg body weight, to be given orally once daily according to the following regime: Weight of cat (kg)
| FORTEKOR* 2.5
| 2.5 - 5
| 1 tablet
| >5 - 10
| 2 tablets
|
Fortekor can be given with or without food. The duration of the treatment will be unlimited. Contra-indications, warnings, etc
For animal treatment only. For oral use only. Wash hands after use. In man, the combination of ACE Inhibitors and NSAIDS can lead to reduced antihypertensive efficacy or impaired renal function. Therefore concurrent use of NSAIDS should be considered with care.
Dogs
Transient signs of hypotension such as tiredness or dizziness may appear in rare cases. Interactions with potassium preserving drugs like spironolactone, triamteren or amilorid cannot be ruled out. It is recommended to monitor plasma potassium levels when using benazepril in combination with a potassium sparing diuretic. As with other ACE inhibitors, the use of hypotensive medicinal products or anaesthetics with a hypotensive effect may add to the anti-hypertensive effect of benazepril. The safety of FORTEKOR* has not been tested in breeding, pregnant or lactating dogs so should be used only if justified clinically, considering the risk/benefit ratio. As is routine in cases of renal insufficiency, it is recommended to monitor plasma urea and creatinine concentrations. Do not use in any dog that has evidence of cardiac output failure due to aortic stenosis.
Cats
Fortekor may increase plasma creatinine concentrations at the start of the therapy. This effect is related to the therapeutic effect of the product in reducing blood pressure and therefore is not necessarily a reason to stop therapy in the absence of other signs. As is routine in cases of renal insufficiency, it is recommended to monitor plasma urea and creatinine concentrations and erythrocyte counts. Fortekor reduced erythrocyte counts in normal cats at high doses, but this effect was not observed at the recommended dose during clinical trials in cats with chronic renal insufficiency. Fortekor may increase food consumption and body weight in cats. The combination of Fortekor and other anti-hypertensive agents (eg. calcium channel blockers, β-blockers or diuretics), anaesthetics or sedatives may lead to additive hypotensive effects. Fortekor is not recommended for breeding cats, pregnant or lactating queens. The safety and efficacy of Fortekor has not been established in cats below 2.5kg. ACE inhibitors have been found to be teratogenic in the 2nd and 3rd trimesters in other species.
Pharmaceutical precautions
Store in a dry place. Do not store above 25°C. Each time an unused half tablet is stored, it should be returned to the open blister space, inserted back into the cardboard box and kept in a safe place out of reach of children.
Legal category
POM-V
Packaging Quantities
Plastic blister packs each containing 14 tablets.
Individual pack containing 2 blisters (Fortekor* 2.5)
Individual pack containing 4 blisters (Fortekor* 2.5)
Disposal
Dispose of used packaging in the household refuse. Unused product should be returned to the veterinary surgeon.
Further information
No evidence of renal toxicity to FORTEKOR* has been observed in dogs during clinical trials. The biliary excretion of benazeprilat means there is little risk of bioaccumulation in dogs and cats with impaired renal function.
Marketing authorisation numbers
FORTEKOR*2.5: VM 12501/4129.
Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction
Company name: Novartis Animal Health UK Ltd
Address: Frimley Business Park
Frimley
Camberley
Surrey
GU16 7SR
Telephone: 01276 694402
Fax: 01276 694403
Presentation Fortekor 2.5
Palatable beige, ovaloid tablets which are scored on both sides: 2.5 mg benazepril hydrochloride.
Uses
FORTEKOR* is indicated for the treatment of heart failure in dogs and
chronic renal insufficiency in cats. The active ingredient is
benazepril. After oral administration, benazepril is rapidly absorbed
from the gastrointestinal tract and hydrolysed into benazeprilat, a
highly specific and potent inhibitor of angiotensin converting enzyme
(ACE). FORTEKOR* produces significant inhibition of plasma ACE activity
for more than 24 hours after a single dose in cats and dogs. Inhibition
of ACE leads to reduced conversion of inactive angiotensin I into
angiotensin II and therefore reduction in the effects mediated by
angiotensin II, including vasoconstriction of both arteries and veins,
retention of sodium and water by the kidney and remodelling effects
(including pathological cardiac hypertrophy and degenerative renal
changes).
In dogs with heart failure, FORTEKOR* lowers the blood pressure and
volume loading on the heart. FORTEKOR* leads to a significant extension
of the life span of dogs with heart failure and also improves clinical
signs, notably reduction in coughing and improvement of the quality of
life.
In contrast with other ACE inhibitors, benazeprilat is excreted equally
by both biliary and urinary routes in dogs and primarily via the biliary
route in cats and therefore no adjustment of the dose of FORTEKOR* is
necessary in the treatment of cats with renal insufficiency.
In cats with chronic renal insufficiency, Fortekor reduces the protein
loss in urine and lowers the systemic and intraglomerular blood
pressure. Reduction in glomerular hypertension retards the progression
of kidney disease by inhibition of further damage to the kidneys.
Fortekor increases the appetite, quality of life and the survival time
of the cats, particularly in advanced disease.
Dosage and administration
Heart failure in dogs
The recommended dose is 0.25-0.5 mg benazepril hydrochloride/kg
bodyweight, to be given orally once daily according to the tabulated
heart failure dosage regime:
Heart failure dosage regime
|
| Fortekor 2.5
| Weight of dog (kg)
| Standard dose
| Double dose
| 2.5 - <5
| 0.5 tablet
| 1 tablet
| 5 - 10
| 1 tablet
| 2 tablets
|
FORTEKOR* can be given with or without food. The duration of treatment
is unlimited. The dose may be doubled, still administered once daily if
judged clinically necessary and advised by the veterinary surgeon.
FORTEKOR* may be given in combination with digoxin, diuretics and
anti-arrhythmic drugs as necessary.
Chronic renal insufficiency in cats
The recommended dose is 0.5-1.0 mg benazepril hydrochloride/kg body
weight, to be given orally once daily according to the following regime: Weight of cat (kg)
| FORTEKOR* 2.5
| 2.5 - 5
| 1 tablet
| >5 - 10
| 2 tablets
|
Fortekor can be given with or without food. The duration of the treatment will be unlimited. Contra-indications, warnings, etc
For animal treatment only. For oral use only. Wash hands after use. In
man, the combination of ACE Inhibitors and NSAIDS can lead to reduced
antihypertensive efficacy or impaired renal function. Therefore
concurrent use of NSAIDS should be considered with care.
Dogs
Transient signs of hypotension such as tiredness or dizziness may appear
in rare cases. Interactions with potassium preserving drugs like
spironolactone, triamteren or amilorid cannot be ruled out. It is
recommended to monitor plasma potassium levels when using benazepril in
combination with a potassium sparing diuretic. As with other ACE
inhibitors, the use of hypotensive medicinal products or anaesthetics
with a hypotensive effect may add to the anti-hypertensive effect of
benazepril. The safety of FORTEKOR* has not been tested in breeding,
pregnant or lactating dogs so should be used only if justified
clinically, considering the risk/benefit ratio. As is routine in cases
of renal insufficiency, it is recommended to monitor plasma urea and
creatinine concentrations. Do not use in any dog that has evidence of
cardiac output failure due to aortic stenosis.
Cats
Fortekor may increase plasma creatinine concentrations at the start of
the therapy. This effect is related to the therapeutic effect of the
product in reducing blood pressure and therefore is not necessarily a
reason to stop therapy in the absence of other signs. As is routine in
cases of renal insufficiency, it is recommended to monitor plasma urea
and creatinine concentrations and erythrocyte counts. Fortekor reduced
erythrocyte counts in normal cats at high doses, but this effect was not
observed at the recommended dose during clinical trials in cats with
chronic renal insufficiency. Fortekor may increase food consumption and
body weight in cats. The combination of Fortekor and other
anti-hypertensive agents (eg. calcium channel blockers, β-blockers or
diuretics), anaesthetics or sedatives may lead to additive hypotensive
effects. Fortekor is not recommended for breeding cats, pregnant or
lactating queens. The safety and efficacy of Fortekor has not been
established in cats below 2.5kg. ACE inhibitors have been found to be
teratogenic in the 2nd and 3rd trimesters in other species.
Pharmaceutical precautions
Store in a dry place. Do not store above 25°C. Each time an unused half
tablet is stored, it should be returned to the open blister space,
inserted back into the cardboard box and kept in a safe place out of
reach of children.
Legal category
POM-V
Packaging Quantities
Plastic blister packs each containing 14 tablets.
Individual pack containing 2 blisters (Fortekor* 2.5)
Individual pack containing 4 blisters (Fortekor* 2.5)
Disposal
Dispose of used packaging in the household refuse. Unused product should be returned to the veterinary surgeon.
Further information
No evidence of renal toxicity to FORTEKOR* has been observed in dogs
during clinical trials. The biliary excretion of benazeprilat means
there is little risk of bioaccumulation in dogs and cats with impaired
renal function.
Marketing authorisation numbers
FORTEKOR*2.5: VM 12501/4129.
 Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction
Company name: Novartis Animal Health UK Ltd
Address: Frimley Business Park
Frimley
Camberley
Surrey
GU16 7SR
Telephone: 01276 694402
Fax: 01276 694403
Presentation Fortekor 2.5
Palatable beige, ovaloid tablets which are scored on both sides: 2.5 mg benazepril hydrochloride.
Uses
FORTEKOR* is indicated for the treatment of heart failure in dogs and
chronic renal insufficiency in cats. The active ingredient is
benazepril. After oral administration, benazepril is rapidly absorbed
from the gastrointestinal tract and hydrolysed into benazeprilat, a
highly specific and potent inhibitor of angiotensin converting enzyme
(ACE). FORTEKOR* produces significant inhibition of plasma ACE activity
for more than 24 hours after a single dose in cats and dogs. Inhibition
of ACE leads to reduced conversion of inactive angiotensin I into
angiotensin II and therefore reduction in the effects mediated by
angiotensin II, including vasoconstriction of both arteries and veins,
retention of sodium and water by the kidney and remodelling effects
(including pathological cardiac hypertrophy and degenerative renal
changes).
In dogs with heart failure, FORTEKOR* lowers the blood pressure and
volume loading on the heart. FORTEKOR* leads to a significant extension
of the life span of dogs with heart failure and also improves clinical
signs, notably reduction in coughing and improvement of the quality of
life.
In contrast with other ACE inhibitors, benazeprilat is excreted equally
by both biliary and urinary routes in dogs and primarily via the biliary
route in cats and therefore no adjustment of the dose of FORTEKOR* is
necessary in the treatment of cats with renal insufficiency.
In cats with chronic renal insufficiency, Fortekor reduces the protein
loss in urine and lowers the systemic and intraglomerular blood
pressure. Reduction in glomerular hypertension retards the progression
of kidney disease by inhibition of further damage to the kidneys.
Fortekor increases the appetite, quality of life and the survival time
of the cats, particularly in advanced disease.
Dosage and administration
Heart failure in dogs
The recommended dose is 0.25-0.5 mg benazepril hydrochloride/kg
bodyweight, to be given orally once daily according to the tabulated
heart failure dosage regime:
Heart failure dosage regime
|
| Fortekor 2.5
| Weight of dog (kg)
| Standard dose
| Double dose
| 2.5 - <5
| 0.5 tablet
| 1 tablet
| 5 - 10
| 1 tablet
| 2 tablets
|
FORTEKOR* can be given with or without food. The duration of treatment
is unlimited. The dose may be doubled, still administered once daily if
judged clinically necessary and advised by the veterinary surgeon.
FORTEKOR* may be given in combination with digoxin, diuretics and
anti-arrhythmic drugs as necessary.
Chronic renal insufficiency in cats
The recommended dose is 0.5-1.0 mg benazepril hydrochloride/kg body
weight, to be given orally once daily according to the following regime: Weight of cat (kg)
| FORTEKOR* 2.5
| 2.5 - 5
| 1 tablet
| >5 - 10
| 2 tablets
|
Fortekor can be given with or without food. The duration of the treatment will be unlimited. Contra-indications, warnings, etc
For animal treatment only. For oral use only. Wash hands after use. In
man, the combination of ACE Inhibitors and NSAIDS can lead to reduced
antihypertensive efficacy or impaired renal function. Therefore
concurrent use of NSAIDS should be considered with care.
Dogs
Transient signs of hypotension such as tiredness or dizziness may appear
in rare cases. Interactions with potassium preserving drugs like
spironolactone, triamteren or amilorid cannot be ruled out. It is
recommended to monitor plasma potassium levels when using benazepril in
combination with a potassium sparing diuretic. As with other ACE
inhibitors, the use of hypotensive medicinal products or anaesthetics
with a hypotensive effect may add to the anti-hypertensive effect of
benazepril. The safety of FORTEKOR* has not been tested in breeding,
pregnant or lactating dogs so should be used only if justified
clinically, considering the risk/benefit ratio. As is routine in cases
of renal insufficiency, it is recommended to monitor plasma urea and
creatinine concentrations. Do not use in any dog that has evidence of
cardiac output failure due to aortic stenosis.
Cats
Fortekor may increase plasma creatinine concentrations at the start of
the therapy. This effect is related to the therapeutic effect of the
product in reducing blood pressure and therefore is not necessarily a
reason to stop therapy in the absence of other signs. As is routine in
cases of renal insufficiency, it is recommended to monitor plasma urea
and creatinine concentrations and erythrocyte counts. Fortekor reduced
erythrocyte counts in normal cats at high doses, but this effect was not
observed at the recommended dose during clinical trials in cats with
chronic renal insufficiency. Fortekor may increase food consumption and
body weight in cats. The combination of Fortekor and other
anti-hypertensive agents (eg. calcium channel blockers, β-blockers or
diuretics), anaesthetics or sedatives may lead to additive hypotensive
effects. Fortekor is not recommended for breeding cats, pregnant or
lactating queens. The safety and efficacy of Fortekor has not been
established in cats below 2.5kg. ACE inhibitors have been found to be
teratogenic in the 2nd and 3rd trimesters in other species.
Pharmaceutical precautions
Store in a dry place. Do not store above 25°C. Each time an unused half
tablet is stored, it should be returned to the open blister space,
inserted back into the cardboard box and kept in a safe place out of
reach of children.
Legal category
POM-V
Packaging Quantities
Plastic blister packs each containing 14 tablets.
Individual pack containing 2 blisters (Fortekor* 2.5)
Individual pack containing 4 blisters (Fortekor* 2.5)
Disposal
Dispose of used packaging in the household refuse. Unused product should be returned to the veterinary surgeon.
Further information
No evidence of renal toxicity to FORTEKOR* has been observed in dogs
during clinical trials. The biliary excretion of benazeprilat means
there is little risk of bioaccumulation in dogs and cats with impaired
renal function.
Marketing authorisation numbers
FORTEKOR*2.5: VM 12501/4129.
Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction
Company name: Novartis Animal Health UK Ltd
Address: Frimley Business Park
Frimley
Camberley
Surrey
GU16 7SR
Telephone: 01276 694402
Fax: 01276 694403
Presentation
Fortekor Flavour 5mg & 20mg
Tablet.
Beige to light brown, ovaloid, divisible, palatable tablet scored on both sides.
5 mg benazepril hydrochloride (Fortekor Flavour 5)
20mg benazepril hydrochloride (Fortekor Flavour 20)
Uses
FORTEKOR FLAVOUR* is indicated for the treatment of congestive heart
failure in dogs. The active ingredient is benazepril hydrochloride.
After oral administration, benazepril is rapidly absorbed from the
gastrointestinal tract and hydrolysed into benazeprilat, a highly
selective and potent inhibitor of angiotensin converting enzyme (ACE).
FORTEKOR FLAVOUR* produces significant inhibition of plasma ACE activity
for more than 24 hours after a single dose in dogs. Inhibition of ACE
prevents the conversion of inactive angiotensin I into angiotensin II
and therefore reduction in the effects mediated by angiotensin II,
including vasoconstriction of both arteries and veins, retention of
sodium and water by the kidney and remodelling effects (including
pathological cardiac hypertrophy and degenerative renal changes).
In dogs with congestive heart failure, FORTEKOR FLAVOUR* lowers the
blood pressure and volume loading on the heart. FORTEKOR FLAVOUR* leads
to an extension of the life span of dogs with congestive heart failure
and also improves clinical signs, notably reduction in coughing and
improvement of the quality of life.
Benazeprilat is excreted equally by both biliary and urinary routes in
dogs. The clearance of benazeprilat is not affected in dogs with
impaired renal function and therefore, no adjustment of FORTEKOR
FLAVOUR* dose is required in cases of renal insufficiency.
Dosage and administration
The recommended dose is 0.25-0.5 mg benazepril hydrochloride/kg
bodyweight, to be given orally once daily according to the tabulated
congestive heart failure dosage regime
Heart failure dosage regime
|
|
|
| Fortekor Flavour 5
| Fortekor Flavour 20
| Weight of dog (kg)
|
|
| Standard dose
| Double dose
| Standard dose
| Double dose
| 5 - 10
|
|
| 0.5 tablet
| 1 tablet
|
|
| 11 - 20
|
|
| 1 tablet
| 2 tablets
|
|
| 21 - 40
|
|
|
|
| 0.5 tablet
| 1 tablet
| 41 - 80
|
|
|
|
| 1 tablet
| 2 tablets
|
FORTEKOR FLAVOUR* are flavoured tablets which are taken voluntarily by
dogs and can be given with or without food. The duration of treatment is
unlimited. The dose may be doubled, still administered once daily if
judged clinically necessary and advised by the veterinary surgeon. In
dogs with heart failure, benazepril hydrochloride has been given in
combination with digoxin, diuretics and anti-arrhythmic drugs without
demonstrable adverse interactions. Contra-indications, warnings, etc
For animal treatment only. For oral use only. Wash hands after use.
Pregnant women should take special care to avoid accidental exposure
because ACE inhibitors have been found to affect the unborn child after
oral exposure during pregnancy in hums. In case of accidental ingestion
by children, seek medical advice immediately and show the doctor this
warning.
In man, the combination of ACE Inhibitors and NSAIDS can lead to reduced
antihypertensive efficacy or impaired renal function. Therefore
concurrent use of NSAIDS should be considered with care.
Transient signs of hypotension such as tiredness or dizziness may appear
in rare cases. Interactions with potassium preserving drugs like
spironolactone, triamteren or amilorid cannot be ruled out. It is
recommended to monitor plasma potassium levels when using benazepril in
combination with a potassium sparing diuretic. As with other ACE
inhibitors, the use of hypotensive medicinal products (e.g. calcium
channel blockers, B-blockers or diuretics) or anaesthetics with a
hypotensive effect may add to the anti-hypertensive effect of
benazepril. Renal function and signs of hypotension (lethargy, weakness
etc.) should be monitored closely and treated as necessary.
The safety of FORTEKOR FLAVOUR* has not been tested in breeding,
pregnant or lactating dogs so should be used only if justified
clinically, considering the risk/benefit ratio. ACE inhibitors have been
found to be teratogenic in the second and third trimesters in other
species.
As is routine in cases of renal insufficiency, it is recommended to
monitor plasma urea and creatinine concentrations. Do not use in any dog
that has evidence of cardiac output failure due to aortic stenosis.
Pharmaceutical precautions
Fortekor Flavour 5: Do not store above 25oC.
Fortekor Flavour 20: No special storage conditions required.
Each time an unused half tablet is stored, it should be returned to the
open blister space, inserted back into the cardboard box and kept in a
safe place out of reach of children. Tablet halves should be used within
2 days.
Legal category
POM-V
Packaging Quantities
Cardboard box with
Fortekor Flavour 5:
Aluminium blister packs each containing 14 tablets
Packs containing 2 blisters (28 tablets).
Packs containing 4 blisters (56 tablets)
Fortekor Flavour 20:
Aluminium blister packs each containing 14 tablets
Pack containing 2 blisters (28 tablets)
Disposal
Any unused product or waste material should be disposed of in accordance
with local requirements. Unused product should be returned to the
veterinary surgeon.
Further information
No evidence of renal toxicity to benazepril hydrochloride has been
observed in dogs during clinical trials. The biliary excretion of
benazeprilat means there is little risk of bioaccumulation in dogs with
impaired renal function.
Benazepril hydrochloride is well tolerated in the target species. In
normal dogs, overdosage up to 200-fold was asymptomatic. Transient
reversible hypotension may occur in cases of accidental overdosage.
Therapy should consist of intravenous infusion of warm, isotonic saline.
Marketing authorisation number
FORTEKOR FLAVOUR *5: VM 12501/4167.
FORTEKOR FLAVOUR *20: VM 12501/4168.
Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction
Company name: Novartis Animal Health UK Ltd
Address: Frimley Business Park
Frimley
Camberley
Surrey
GU16 7SR
Telephone: 01276 694402
Fax: 01276 694403
Presentation
Fortekor Flavour 5mg & 20mg
Tablet.
Beige to light brown, ovaloid, divisible, palatable tablet scored on both sides.
5 mg benazepril hydrochloride (Fortekor Flavour 5)
20mg benazepril hydrochloride (Fortekor Flavour 20)
Uses
FORTEKOR FLAVOUR* is indicated for the treatment of congestive heart
failure in dogs. The active ingredient is benazepril hydrochloride.
After oral administration, benazepril is rapidly absorbed from the
gastrointestinal tract and hydrolysed into benazeprilat, a highly
selective and potent inhibitor of angiotensin converting enzyme (ACE).
FORTEKOR FLAVOUR* produces significant inhibition of plasma ACE activity
for more than 24 hours after a single dose in dogs. Inhibition of ACE
prevents the conversion of inactive angiotensin I into angiotensin II
and therefore reduction in the effects mediated by angiotensin II,
including vasoconstriction of both arteries and veins, retention of
sodium and water by the kidney and remodelling effects (including
pathological cardiac hypertrophy and degenerative renal changes).
In dogs with congestive heart failure, FORTEKOR FLAVOUR* lowers the
blood pressure and volume loading on the heart. FORTEKOR FLAVOUR* leads
to an extension of the life span of dogs with congestive heart failure
and also improves clinical signs, notably reduction in coughing and
improvement of the quality of life.
Benazeprilat is excreted equally by both biliary and urinary routes in
dogs. The clearance of benazeprilat is not affected in dogs with
impaired renal function and therefore, no adjustment of FORTEKOR
FLAVOUR* dose is required in cases of renal insufficiency.
Dosage and administration
The recommended dose is 0.25-0.5 mg benazepril hydrochloride/kg
bodyweight, to be given orally once daily according to the tabulated
congestive heart failure dosage regime
Heart failure dosage regime
|
|
|
| Fortekor Flavour 5
| Fortekor Flavour 20
| Weight of dog (kg)
|
|
| Standard dose
| Double dose
| Standard dose
| Double dose
| 5 - 10
|
|
| 0.5 tablet
| 1 tablet
|
|
| 11 - 20
|
|
| 1 tablet
| 2 tablets
|
|
| 21 - 40
|
|
|
|
| 0.5 tablet
| 1 tablet
| 41 - 80
|
|
|
|
| 1 tablet
| 2 tablets
|
FORTEKOR FLAVOUR* are flavoured tablets which are taken voluntarily by
dogs and can be given with or without food. The duration of treatment is
unlimited. The dose may be doubled, still administered once daily if
judged clinically necessary and advised by the veterinary surgeon. In
dogs with heart failure, benazepril hydrochloride has been given in
combination with digoxin, diuretics and anti-arrhythmic drugs without
demonstrable adverse interactions. Contra-indications, warnings, etc
For animal treatment only. For oral use only. Wash hands after use.
Pregnant women should take special care to avoid accidental exposure
because ACE inhibitors have been found to affect the unborn child after
oral exposure during pregnancy in hums. In case of accidental ingestion
by children, seek medical advice immediately and show the doctor this
warning.
In man, the combination of ACE Inhibitors and NSAIDS can lead to reduced
antihypertensive efficacy or impaired renal function. Therefore
concurrent use of NSAIDS should be considered with care.
Transient signs of hypotension such as tiredness or dizziness may appear
in rare cases. Interactions with potassium preserving drugs like
spironolactone, triamteren or amilorid cannot be ruled out. It is
recommended to monitor plasma potassium levels when using benazepril in
combination with a potassium sparing diuretic. As with other ACE
inhibitors, the use of hypotensive medicinal products (e.g. calcium
channel blockers, B-blockers or diuretics) or anaesthetics with a
hypotensive effect may add to the anti-hypertensive effect of
benazepril. Renal function and signs of hypotension (lethargy, weakness
etc.) should be monitored closely and treated as necessary.
The safety of FORTEKOR FLAVOUR* has not been tested in breeding,
pregnant or lactating dogs so should be used only if justified
clinically, considering the risk/benefit ratio. ACE inhibitors have been
found to be teratogenic in the second and third trimesters in other
species.
As is routine in cases of renal insufficiency, it is recommended to
monitor plasma urea and creatinine concentrations. Do not use in any dog
that has evidence of cardiac output failure due to aortic stenosis.
Pharmaceutical precautions
Fortekor Flavour 5: Do not store above 25oC.
Fortekor Flavour 20: No special storage conditions required.
Each time an unused half tablet is stored, it should be returned to the
open blister space, inserted back into the cardboard box and kept in a
safe place out of reach of children. Tablet halves should be used within
2 days.
Legal category
POM-V
Packaging Quantities
Cardboard box with
Fortekor Flavour 5:
Aluminium blister packs each containing 14 tablets
Packs containing 2 blisters (28 tablets).
Packs containing 4 blisters (56 tablets)
Fortekor Flavour 20:
Aluminium blister packs each containing 14 tablets
Pack containing 2 blisters (28 tablets)
Disposal
Any unused product or waste material should be disposed of in accordance
with local requirements. Unused product should be returned to the
veterinary surgeon.
Further information
No evidence of renal toxicity to benazepril hydrochloride has been
observed in dogs during clinical trials. The biliary excretion of
benazeprilat means there is little risk of bioaccumulation in dogs with
impaired renal function.
Benazepril hydrochloride is well tolerated in the target species. In
normal dogs, overdosage up to 200-fold was asymptomatic. Transient
reversible hypotension may occur in cases of accidental overdosage.
Therapy should consist of intravenous infusion of warm, isotonic saline.
Marketing authorisation number
FORTEKOR FLAVOUR *5: VM 12501/4167.
FORTEKOR FLAVOUR *20: VM 12501/4168.
Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction
Company name: Novartis Animal Health UK Ltd
Address: Frimley Business Park
Frimley
Camberley
Surrey
GU16 7SR
Telephone: 01276 694402
Fax: 01276 694403
Presentation
Fortekor Flavour 5mg & 20mg
Tablet.
Beige to light brown, ovaloid, divisible, palatable tablet scored on both sides.
5 mg benazepril hydrochloride (Fortekor Flavour 5)
20mg benazepril hydrochloride (Fortekor Flavour 20)
Uses
FORTEKOR FLAVOUR* is indicated for the treatment of congestive heart
failure in dogs. The active ingredient is benazepril hydrochloride.
After oral administration, benazepril is rapidly absorbed from the
gastrointestinal tract and hydrolysed into benazeprilat, a highly
selective and potent inhibitor of angiotensin converting enzyme (ACE).
FORTEKOR FLAVOUR* produces significant inhibition of plasma ACE activity
for more than 24 hours after a single dose in dogs. Inhibition of ACE
prevents the conversion of inactive angiotensin I into angiotensin II
and therefore reduction in the effects mediated by angiotensin II,
including vasoconstriction of both arteries and veins, retention of
sodium and water by the kidney and remodelling effects (including
pathological cardiac hypertrophy and degenerative renal changes).
In dogs with congestive heart failure, FORTEKOR FLAVOUR* lowers the
blood pressure and volume loading on the heart. FORTEKOR FLAVOUR* leads
to an extension of the life span of dogs with congestive heart failure
and also improves clinical signs, notably reduction in coughing and
improvement of the quality of life.
Benazeprilat is excreted equally by both biliary and urinary routes in
dogs. The clearance of benazeprilat is not affected in dogs with
impaired renal function and therefore, no adjustment of FORTEKOR
FLAVOUR* dose is required in cases of renal insufficiency.
Dosage and administration
The recommended dose is 0.25-0.5 mg benazepril hydrochloride/kg
bodyweight, to be given orally once daily according to the tabulated
congestive heart failure dosage regime
Heart failure dosage regime
|
|
|
| Fortekor Flavour 5
| Fortekor Flavour 20
| Weight of dog (kg)
|
|
| Standard dose
| Double dose
| Standard dose
| Double dose
| 5 - 10
|
|
| 0.5 tablet
| 1 tablet
|
|
| 11 - 20
|
|
| 1 tablet
| 2 tablets
|
|
| 21 - 40
|
|
|
|
| 0.5 tablet
| 1 tablet
| 41 - 80
|
|
|
|
| 1 tablet
| 2 tablets
|
FORTEKOR FLAVOUR* are flavoured tablets which are taken voluntarily by
dogs and can be given with or without food. The duration of treatment is
unlimited. The dose may be doubled, still administered once daily if
judged clinically necessary and advised by the veterinary surgeon. In
dogs with heart failure, benazepril hydrochloride has been given in
combination with digoxin, diuretics and anti-arrhythmic drugs without
demonstrable adverse interactions. Contra-indications, warnings, etc
For animal treatment only. For oral use only. Wash hands after use.
Pregnant women should take special care to avoid accidental exposure
because ACE inhibitors have been found to affect the unborn child after
oral exposure during pregnancy in hums. In case of accidental ingestion
by children, seek medical advice immediately and show the doctor this
warning.
In man, the combination of ACE Inhibitors and NSAIDS can lead to reduced
antihypertensive efficacy or impaired renal function. Therefore
concurrent use of NSAIDS should be considered with care.
Transient signs of hypotension such as tiredness or dizziness may appear
in rare cases. Interactions with potassium preserving drugs like
spironolactone, triamteren or amilorid cannot be ruled out. It is
recommended to monitor plasma potassium levels when using benazepril in
combination with a potassium sparing diuretic. As with other ACE
inhibitors, the use of hypotensive medicinal products (e.g. calcium
channel blockers, B-blockers or diuretics) or anaesthetics with a
hypotensive effect may add to the anti-hypertensive effect of
benazepril. Renal function and signs of hypotension (lethargy, weakness
etc.) should be monitored closely and treated as necessary.
The safety of FORTEKOR FLAVOUR* has not been tested in breeding,
pregnant or lactating dogs so should be used only if justified
clinically, considering the risk/benefit ratio. ACE inhibitors have been
found to be teratogenic in the second and third trimesters in other
species.
As is routine in cases of renal insufficiency, it is recommended to
monitor plasma urea and creatinine concentrations. Do not use in any dog
that has evidence of cardiac output failure due to aortic stenosis.
Pharmaceutical precautions
Fortekor Flavour 5: Do not store above 25oC.
Fortekor Flavour 20: No special storage conditions required.
Each time an unused half tablet is stored, it should be returned to the
open blister space, inserted back into the cardboard box and kept in a
safe place out of reach of children. Tablet halves should be used within
2 days.
Legal category
POM-V
Packaging Quantities
Cardboard box with
Fortekor Flavour 5:
Aluminium blister packs each containing 14 tablets
Packs containing 2 blisters (28 tablets).
Packs containing 4 blisters (56 tablets)
Fortekor Flavour 20:
Aluminium blister packs each containing 14 tablets
Pack containing 2 blisters (28 tablets)
Disposal
Any unused product or waste material should be disposed of in accordance
with local requirements. Unused product should be returned to the
veterinary surgeon.
Further information
No evidence of renal toxicity to benazepril hydrochloride has been
observed in dogs during clinical trials. The biliary excretion of
benazeprilat means there is little risk of bioaccumulation in dogs with
impaired renal function.
Benazepril hydrochloride is well tolerated in the target species. In
normal dogs, overdosage up to 200-fold was asymptomatic. Transient
reversible hypotension may occur in cases of accidental overdosage.
Therapy should consist of intravenous infusion of warm, isotonic saline.
Marketing authorisation number
FORTEKOR FLAVOUR *5: VM 12501/4167.
FORTEKOR FLAVOUR *20: VM 12501/4168.
Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication.
Introduction 
Company name: Novartis Animal Health UK Ltd
Address: Frimley Business Park
Frimley
Camberley
Surrey
GU16 7SR
Telephone: 01276 694402
Fax: 01276 694403
Presentation
Fortekor Flavour 5mg & 20mg
Tablet.
Beige to light brown, ovaloid, divisible, palatable tablet scored on both sides.
5 mg benazepril hydrochloride (Fortekor Flavour 5)
20mg benazepril hydrochloride (Fortekor Flavour 20)
Uses
FORTEKOR FLAVOUR* is indicated for the treatment of congestive heart failure in dogs. The active ingredient is benazepril hydrochloride. After oral administration, benazepril is rapidly absorbed from the gastrointestinal tract and hydrolysed into benazeprilat, a highly selective and potent inhibitor of angiotensin converting enzyme (ACE). FORTEKOR FLAVOUR* produces significant inhibition of plasma ACE activity for more than 24 hours after a single dose in dogs. Inhibition of ACE prevents the conversion of inactive angiotensin I into angiotensin II and therefore reduction in the effects mediated by angiotensin II, including vasoconstriction of both arteries and veins, retention of sodium and water by the kidney and remodelling effects (including pathological cardiac hypertrophy and degenerative renal changes).
In dogs with congestive heart failure, FORTEKOR FLAVOUR* lowers the blood pressure and volume loading on the heart. FORTEKOR FLAVOUR* leads to an extension of the life span of dogs with congestive heart failure and also improves clinical signs, notably reduction in coughing and improvement of the quality of life.
Benazeprilat is excreted equally by both biliary and urinary routes in dogs. The clearance of benazeprilat is not affected in dogs with impaired renal function and therefore, no adjustment of FORTEKOR FLAVOUR* dose is required in cases of renal insufficiency.
Dosage and administration
The recommended dose is 0.25-0.5 mg benazepril hydrochloride/kg bodyweight, to be given orally once daily according to the tabulated congestive heart failure dosage regime | Heart failure dosage regime | |
|
|
| Fortekor Flavour 5 | Fortekor Flavour 20 | | Weight of dog (kg) |
|
|
Standard dose |
Double dose |
Standard dose |
Double dose | |
5 - 10 |
|
|
0.5 tablet |
1 tablet |
|
| |
11 - 20 |
|
|
1 tablet |
2 tablets |
|
| |
21 - 40 |
|
|
|
|
0.5 tablet |
1 tablet | |
41 - 80 |
|
|
|
|
1 tablet |
2 tablets |
FORTEKOR FLAVOUR* are flavoured tablets which are taken voluntarily by dogs and can be given with or without food. The duration of treatment is unlimited. The dose may be doubled, still administered once daily if judged clinically necessary and advised by the veterinary surgeon. In dogs with heart failure, benazepril hydrochloride has been given in combination with digoxin, diuretics and anti-arrhythmic drugs without demonstrable adverse interactions.
Contra-indications, warnings, etc
For animal treatment only. For oral use only. Wash hands after use. Pregnant women should take special care to avoid accidental exposure because ACE inhibitors have been found to affect the unborn child after oral exposure during pregnancy in hums. In case of accidental ingestion by children, seek medical advice immediately and show the doctor this warning.
In man, the combination of ACE Inhibitors and NSAIDS can lead to reduced antihypertensive efficacy or impaired renal function. Therefore concurrent use of NSAIDS should be considered with care.
Transient signs of hypotension such as tiredness or dizziness may appear in rare cases. Interactions with potassium preserving drugs like spironolactone, triamteren or amilorid cannot be ruled out. It is recommended to monitor plasma potassium levels when using benazepril in combination with a potassium sparing diuretic. As with other ACE inhibitors, the use of hypotensive medicinal products (e.g. calcium channel blockers, B-blockers or diuretics) or anaesthetics with a hypotensive effect may add to the anti-hypertensive effect of benazepril. Renal function and signs of hypotension (lethargy, weakness etc.) should be monitored closely and treated as necessary.
The safety of FORTEKOR FLAVOUR* has not been tested in breeding, pregnant or lactating dogs so should be used only if justified clinically, considering the risk/benefit ratio. ACE inhibitors have been found to be teratogenic in the second and third trimesters in other species.
As is routine in cases of renal insufficiency, it is recommended to monitor plasma urea and creatinine concentrations. Do not use in any dog that has evidence of cardiac output failure due to aortic stenosis.
Pharmaceutical precautions
Fortekor Flavour 5: Do not store above 25oC.
Fortekor Flavour 20: No special storage conditions required.
Each time an unused half tablet is stored, it should be returned to the open blister space, inserted back into the cardboard box and kept in a safe place out of reach of children. Tablet halves should be used within 2 days.
Legal category
POM-V
Packaging Quantities
Cardboard box with
Fortekor Flavour 5:
Aluminium blister packs each containing 14 tablets
Packs containing 2 blisters (28 tablets).
Packs containing 4 blisters (56 tablets)
Fortekor Flavour 20:
Aluminium blister packs each containing 14 tablets
Pack containing 2 blisters (28 tablets)
Disposal
Any unused product or waste material should be disposed of in accordance with local requirements. Unused product should be returned to the veterinary surgeon.
Further information
No evidence of renal toxicity to benazepril hydrochloride has been observed in dogs during clinical trials. The biliary excretion of benazeprilat means there is little risk of bioaccumulation in dogs with impaired renal function.
Benazepril hydrochloride is well tolerated in the target species. In normal dogs, overdosage up to 200-fold was asymptomatic. Transient reversible hypotension may occur in cases of accidental overdosage. Therapy should consist of intravenous infusion of warm, isotonic saline.
Marketing authorisation number
FORTEKOR FLAVOUR *5: VM 12501/4167.
FORTEKOR FLAVOUR *20: VM 12501/4168.
Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction
Company name: Novartis Animal Health UK Ltd
Address: Frimley Business Park
Frimley
Camberley
Surrey
GU16 7SR
Telephone: 01276 694402
Fax: 01276 694403
Presentation
Fortekor Flavour 5mg & 20mg
Tablet.
Beige to light brown, ovaloid, divisible, palatable tablet scored on both sides.
5 mg benazepril hydrochloride (Fortekor Flavour 5)
20mg benazepril hydrochloride (Fortekor Flavour 20)
Uses
FORTEKOR FLAVOUR* is indicated for the treatment of congestive heart
failure in dogs. The active ingredient is benazepril hydrochloride.
After oral administration, benazepril is rapidly absorbed from the
gastrointestinal tract and hydrolysed into benazeprilat, a highly
selective and potent inhibitor of angiotensin converting enzyme (ACE).
FORTEKOR FLAVOUR* produces significant inhibition of plasma ACE activity
for more than 24 hours after a single dose in dogs. Inhibition of ACE
prevents the conversion of inactive angiotensin I into angiotensin II
and therefore reduction in the effects mediated by angiotensin II,
including vasoconstriction of both arteries and veins, retention of
sodium and water by the kidney and remodelling effects (including
pathological cardiac hypertrophy and degenerative renal changes).
In dogs with congestive heart failure, FORTEKOR FLAVOUR* lowers the
blood pressure and volume loading on the heart. FORTEKOR FLAVOUR* leads
to an extension of the life span of dogs with congestive heart failure
and also improves clinical signs, notably reduction in coughing and
improvement of the quality of life.
Benazeprilat is excreted equally by both biliary and urinary routes in
dogs. The clearance of benazeprilat is not affected in dogs with
impaired renal function and therefore, no adjustment of FORTEKOR
FLAVOUR* dose is required in cases of renal insufficiency.
Dosage and administration
The recommended dose is 0.25-0.5 mg benazepril hydrochloride/kg
bodyweight, to be given orally once daily according to the tabulated
congestive heart failure dosage regime
Heart failure dosage regime
|
|
|
| Fortekor Flavour 5
| Fortekor Flavour 20
| Weight of dog (kg)
|
|
| Standard dose
| Double dose
| Standard dose
| Double dose
| 5 - 10
|
|
| 0.5 tablet
| 1 tablet
|
|
| 11 - 20
|
|
| 1 tablet
| 2 tablets
|
|
| 21 - 40
|
|
|
|
| 0.5 tablet
| 1 tablet
| 41 - 80
|
|
|
|
| 1 tablet
| 2 tablets
|
FORTEKOR FLAVOUR* are flavoured tablets which are taken voluntarily by
dogs and can be given with or without food. The duration of treatment is
unlimited. The dose may be doubled, still administered once daily if
judged clinically necessary and advised by the veterinary surgeon. In
dogs with heart failure, benazepril hydrochloride has been given in
combination with digoxin, diuretics and anti-arrhythmic drugs without
demonstrable adverse interactions. Contra-indications, warnings, etc
For animal treatment only. For oral use only. Wash hands after use.
Pregnant women should take special care to avoid accidental exposure
because ACE inhibitors have been found to affect the unborn child after
oral exposure during pregnancy in hums. In case of accidental ingestion
by children, seek medical advice immediately and show the doctor this
warning.
In man, the combination of ACE Inhibitors and NSAIDS can lead to reduced
antihypertensive efficacy or impaired renal function. Therefore
concurrent use of NSAIDS should be considered with care.
Transient signs of hypotension such as tiredness or dizziness may appear
in rare cases. Interactions with potassium preserving drugs like
spironolactone, triamteren or amilorid cannot be ruled out. It is
recommended to monitor plasma potassium levels when using benazepril in
combination with a potassium sparing diuretic. As with other ACE
inhibitors, the use of hypotensive medicinal products (e.g. calcium
channel blockers, B-blockers or diuretics) or anaesthetics with a
hypotensive effect may add to the anti-hypertensive effect of
benazepril. Renal function and signs of hypotension (lethargy, weakness
etc.) should be monitored closely and treated as necessary.
The safety of FORTEKOR FLAVOUR* has not been tested in breeding,
pregnant or lactating dogs so should be used only if justified
clinically, considering the risk/benefit ratio. ACE inhibitors have been
found to be teratogenic in the second and third trimesters in other
species.
As is routine in cases of renal insufficiency, it is recommended to
monitor plasma urea and creatinine concentrations. Do not use in any dog
that has evidence of cardiac output failure due to aortic stenosis.
Pharmaceutical precautions
Fortekor Flavour 5: Do not store above 25oC.
Fortekor Flavour 20: No special storage conditions required.
Each time an unused half tablet is stored, it should be returned to the
open blister space, inserted back into the cardboard box and kept in a
safe place out of reach of children. Tablet halves should be used within
2 days.
Legal category
POM-V
Packaging Quantities
Cardboard box with
Fortekor Flavour 5:
Aluminium blister packs each containing 14 tablets
Packs containing 2 blisters (28 tablets).
Packs containing 4 blisters (56 tablets)
Fortekor Flavour 20:
Aluminium blister packs each containing 14 tablets
Pack containing 2 blisters (28 tablets)
Disposal
Any unused product or waste material should be disposed of in accordance
with local requirements. Unused product should be returned to the
veterinary surgeon.
Further information
No evidence of renal toxicity to benazepril hydrochloride has been
observed in dogs during clinical trials. The biliary excretion of
benazeprilat means there is little risk of bioaccumulation in dogs with
impaired renal function.
Benazepril hydrochloride is well tolerated in the target species. In
normal dogs, overdosage up to 200-fold was asymptomatic. Transient
reversible hypotension may occur in cases of accidental overdosage.
Therapy should consist of intravenous infusion of warm, isotonic saline.
Marketing authorisation number
FORTEKOR FLAVOUR *5: VM 12501/4167.
FORTEKOR FLAVOUR *20: VM 12501/4168.
|
